RVL Pharmaceuticals PLC
NASDAQ:RVLP
RVL Pharmaceuticals PLC
Operating Income
RVL Pharmaceuticals PLC
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
RVL Pharmaceuticals PLC
NASDAQ:RVLP
|
Operating Income
-$42.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$24.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$10.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$11.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
See Also
What is RVL Pharmaceuticals PLC's Operating Income?
Operating Income
-42.8m
USD
Based on the financial report for Dec 31, 2022, RVL Pharmaceuticals PLC's Operating Income amounts to -42.8m USD.
What is RVL Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 1Y
47%
Over the last year, the Operating Income growth was 47%.